Maryam Lustberg MD, MPH, FASCO
@maryam_lustberg
Followers
9K
Following
29K
Statuses
10K
Breast Oncologist @yalecancer @yalemed @yalebreast Director; @CancerCareMASCC; @jcansurv; @ALLIANCE_org SIC co-Chair; #bcsm #survonc; she/her/hers
New Haven, CT
Joined June 2017
RT @itsnot_pink: PCDI @the_rightdose is again collecting data on the experience of people with MBC regarding treatment, tolerability & QoL.…
0
13
0
RT @DrNicolasHart: Cognitive Function in Cancer and the role of Non-Pharmacological Interventions: An overview o…
0
8
0
RT @CancerCareMASCC: Join us for the 5th Annual @OncoAlert Colloquium, taking place free and online from Feb 3 – 9. MASCC is pleased to be…
0
4
0
RT @OncoAlert: Dear Colleagues The OncoAlert🚨 Network along with our partners at @ESSOnews @ESGO_society @CancerCareMASCC & @SIOGorg inv…
0
31
0
RT @jamecancerdoc: Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology https…
0
18
0
Congratulations to an amazing leader and someone I can count on as a trusted friend @YaleMed @YaleCancer @YaleHemOnc
#WomenInMedicine #WomenInLeadership
With gratitude and excitement, I am happy to share that I’ve been promoted to Professor of Medicine (Oncology). It's been a long journey since my white coat ceremony. @YaleMed @YaleCancer @ericwiner @royherbst 🧵1/6
0
4
32
RT @Larvol: Introducing the Top Oncologists on X for Breast Cancer in 2024. These experts, peer-nominated and socially influential, are dri…
0
20
0
RT @EdEsplin: "we recommend that all #patients with #prostatecancer should be offered comprehensive #germline #genetictesting" #DrNealShore…
0
6
0
0
0
1
INSEMA study important results: In low risk breast cancer (T1, grade 1 or 2, negative axillary US) SNB can be avoided with no impact on iDFS/OS even tho 14% of SNB are + for tumors. Exactly the same as SOUND trial
0
2
3
RT @YaleCancer: Congratulations to @maryam_lustberg and Dr. Patricia LoRusso @AACRPres, two of @oncodaily 100 Influential Women in Oncology…
0
1
0
@DrAmyComander on life style modification studies in breast cancer #survonc #bcsm #supponc @CancerCareMASCC seminar with @raalbany
0
7
13
Amazing work by @LisRavani @JCOOP_ASCO
Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer @JCOOP_ASCO @OncoAlert @oncodaily @maryam_lustberg better to continue endocrine based therapy as long as possible over chemotherapy
0
0
14
RT @CancerCareMASCC: Watch the recording from our recent webinar on Navigating the Evolving Landscape in Early Breast Cancer: https://t.co…
0
5
0
RT @ASCO: Congratulations to Dr. Elizabeth A. Mittendorf on being elected to serve as ASCO President for the 2026-2027 term! Six additional…
0
26
0
RT @LisRavani: Proud to share our work in @JCOOP_ASCO ! 📢Our meta-analysis of 4,899 patients explored the efficacy of different treatment…
0
2
0
RT @oncodaily: 📡Best of 2024 SABCS – San Antonio Breast Cancer Symposium SABCS 2024 showcased groundbreaking advancements in breast cancer…
0
18
0
TULIP study and toxicities led to stopping of further development of this ADC. There are examples albeit rare
@EnriqueSoto8 Long time ago I asked our Med onc colleagues if there was ever a phase 3 paper saying that AE were not manageable, apparently no one could remember one example. mortality is reported separately so you either die from the adverse events or survive and be "manageable"
0
2
12